Osteonectin is an α-granule component involved with thrombospondin in platelet aggregation
Authors: Dr. Clezardin Philippe , Malaval Luc , Trzeciak Marie-Christine , Guichard Josette , Lecompte Thomas , Morel Marie-Christine , Dechavanne Marc , Breton-Gorius Janine , Delmas Pierre D. , Kaplan Cécile 
Published: February 2010

Abstract
We previously showed that thrombospondin, a major α-granule glycoprotein of human platelets, forms a specific complex with osteonectin, a phosphoglycoprotein originally described in bone that is also present in human platelets. The storage organelles and the function of osteonectin in platelets are still unknown. In this study, using electron microscopy in combination with immunogold staining, osteonectin was located within the major storage organelle for platelet-secreted proteins, the α-granules. Furthermore, osteonectin was qualitatively and quantitatively assessed by studying normal platelets and the platelets from a patient with gray platelet syndrome. Gray platelet syndrome is a rare congenital bleeding disorder characterized by a selective deficiency in morphologically recognizable platelet α-granules and in the α-granule secretory proteins. Binding of an iodinated antiosteonectin monoclonal antibody to gray platelet proteins transferred to nitrocellulose from SDS-polyacrylamide gels showed no band corresponding to osteonectin compared to control platelets. Using a polyclonal antiosteonectin antibody-based radioimmunoassay, gray platelets contained 0.2 ± 0.03 ng osteonectin per 106 platelets, which is only 20% of the normal platelet content of osteonectin (0.93 ± 0.16 ng per 106 platelets). Study of the localization of osteonectin to the surface of human platelets demonstrated that a radioiodinated antiosteonectin polyclonal antibody bound specifically to thrombin-stimulated platelets but not to resting platelets. Binding was concentration-dependent, saturable (1710 ± 453 binding sites per platelet, Kd = 1 μM), and inhibited by an excess of cold antiosteonectin polyclonal antibody. No binding was observed on the surface of thrombin-stimulated gray platelets. To gain further insights into the role of osteonectin released from activated platelets, the effect of an antiosteonectin polyclonal antibody was tested on the aggregation of washed platelets. F(ab′)2 fragments from the antiosteonectin polyclonal antibody inhibited in a dose-dependent manner the aggregation of collagen-stimulated, washed human platelets without affecting collagen-induced platelet serotonin release. To characterize the mechanism through which antiosteonectin F(ab′)2 fragments inhibit platelet aggregation, the expression of endogenous thrombospondin (TSP) on the surface of thrombin-activated platelets was studied using 125I-labeled anti-TSP monoclonal antibody P10. The endogenous surface expression of TSP to thrombin-stimulated platelets was significantly inhibited in the presence of antiosteonectin F(ab′)2 fragments (6286 ± 2065 molecules of P10 per platelet) compared to 11,230 ± 766 molecules of P10 per platelet in the presence of nonimmune F(ab′)2 fragments. This inhibitory effect of antiosteonectin F(ab′)2 fragments on the surface expression of endogenous TSP was not mediated by interference with binding of monoclonal antibody P10 to TSP as judged by enzyme-linked immunosorbent assay. In summary, these results demonstrate that osteonectin is an α-granule component that, by binding on the surface of activated platelets, is involved with TSP in the secretion-dependent phase of the platelet aggregation process.